Form 4: Celldex Therapeutics Executive Receives Stock Options

Celldex Therapeutics Executive VP & CSO, Tibor Keler, was granted 115,000 incentive stock options with an exercise price of $34.09.

Summary

• Tibor Keler, Executive VP & Chief Scientific Officer at Celldex Therapeutics, Inc., received a grant of 115,000 incentive stock options.
• The options have an exercise price of $34.09 per share.
• The grant was made under the company's 2021 Omnibus Equity Incentive Plan.
• The earliest transaction date associated with this filing is June 25, 2026.
• Vesting begins with 25% on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event (stock option grant) rather than a significant financial or strategic development for the company.

Positives

• Grant of stock options to a key executive, indicating potential alignment of executive interests with shareholder value.
• The stock options are exercisable at a price of $34.09, suggesting a belief in future stock price appreciation above this level.

Risks

• The value of the stock options is contingent on the future performance of Celldex Therapeutics' stock price.
• If the stock price does not exceed $34.09, the options may not be exercised profitably.

Future Outlook

The vesting schedule indicates a multi-year commitment and aligns with the long-term development of the company's pipeline. The exercise price suggests management's expectation of future stock price appreciation.

Industry Context

StockSavvy.ai notes that the granting of incentive stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and motivate key talent, aligning their financial interests with the long-term success of the company and its shareholders.

Stakeholder Impact

• Shareholders: The grant of options aligns executive incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: This filing is specific to an executive and does not directly detail broader employee compensation or impact.
• Management: Tibor Keler benefits from the potential for future financial gain tied to the company's stock performance.

Next Steps

• The stock options will vest over a period of approximately three years following the grant date.
• The executive can exercise the options if the stock price exceeds the exercise price of $34.09.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Executive Compensation, Incentive Stock Option, Tibor Keler, SEC Filing